Engineering controllable CAR T-cell therapies: from binary safety switches to programmable immunity
Chimeric antigen receptor (CAR) T-cell therapy has revolutionised cancer gene therapy, yet its expansion into solid tumours is hindered by a critical vulnerability: the autonomous, “always-on” nature of conventional CAR constructs. This unregulated act…